We see NXU.DE stock trading at €71.20 in the pre-market on 06 Mar 2026, setting up a potential oversold bounce. Price sits just below the 50-day average of €71.30 and above the 200-day average of €70.79, with light volume at 150 shares versus a 50-day average of 729. Fundamentals show EPS €1.97 and PE 36.14, while recent three‑month performance is down 0.97%. The mismatch between thin trading and stable fundamentals creates a short‑term mean reversion trade idea for traders watching XETRA

NXU.DE stock: pre-market price, volume and intraday levels

NXU.DE stock opens pre-market at €71.20 with today’s range locked at €71.20. Volume is thin at 150.00 shares versus an average of 729.00. Key technical levels are support €67.00 (year low) and resistance €74.30 (year high). Traders should watch for a volume lift above 729.00 to validate an oversold bounce.

Fundamentals and valuation for NXU.DE stock

Nexus AG shows steady margins and cash flow. Revenue per share is €16.26, operating cash flow per share €3.89, and free cash flow per share €3.28. The company reports EPS €1.97 and a PE ratio 36.14. Price to sales is 4.38 and price to book is 4.07, above healthcare sector averages. These ratios suggest premium valuation against peers despite strong cash conversion metrics.

Technical setup: oversold bounce case for NXU.DE stock

Price sits near short and medium moving averages, a common bounce area. NXU.DE’s three‑month return is -0.97% while year‑to‑date is 3.94%, indicating a modest pullback. Low volume and price near the 50/200 averages can produce a mean reversion pop if buyers return. Traders should look for a spike in intraday volume and a break above €72.50 as a first validation level.

Meyka AI grade and NXU.DE stock forecast

Meyka AI rates NXU.DE with a score out of 100: 78.66 / 100 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €85.39, implying +19.96% upside from the current €71.20. Forecasts are model‑based projections and not guarantees.

Risks, catalysts and NXU.DE stock outlook

Key catalysts include contract wins in hospital IT and growth in cloud outsourcing. Risks include valuation compression from a high PE 36.14 and thin intraday liquidity. Earnings timing shows the next announced date was in 2025-11-04, so monitor company updates and sector headlines. A confirmed bounce should be accompanied by higher volume and positive sector momentum in Healthcare.

Trading plan, price targets and NXU.DE stock strategy

For an oversold bounce trade, set an initial target near the Meyka base forecast and a bull target higher. Conservative target: €80.00. Meyka base forecast: €85.39. Bull target (3‑year view): €104.74. Stop management matters given average volume. Use a stop under €67.00 or position‑size to limit downside.

Final Thoughts

NXU.DE stock looks set for a short‑term oversold bounce if volume returns to normal. At €71.20 pre-market on 06 Mar 2026, price is near moving averages while fundamentals remain solid: EPS €1.97, PE 36.14, and strong free cash flow per share €3.28. Meyka AI’s forecast model projects a yearly price of €85.39, implying +19.96% upside from today’s price. That projection supports a tactical bounce trade with a conservative €80.00 target and a base target at €85.39, while a multi‑year stretch target is €104.74. Remember, thin volume at 150.00 shares raises execution risk. Use clear entry triggers, volume confirmation, and disciplined stops. Forecasts are model‑based projections and not guarantees, and this analysis is informational, not investment advice. See the company site for filings and the Meyka page for live updates: Nexus AG and Nexus on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.